25-Hydroxyvitamin D levels and cognitive performance and decline in elderly men

Y. Slinin, M. L. Paudel, B. C. Taylor, H. A. Fink, A. Ishani, M. T. Canales, K. Yaffe, E. Barrett-Connor, Eric Orwoll, J. M. Shikany, E. S. Leblanc, J. A. Cauley, K. E. Ensrud

Research output: Contribution to journalArticle

150 Citations (Scopus)

Abstract

OBJECTIVE: To test the hypothesis that lower 25-hydroxyvitamin D [25(OH)D] levels are associated with a greater likelihood of cognitive impairment and risk of cognitive decline. METHODS: We measured 25(OH)D and assessed cognitive function using the Modified Mini-Mental State Examination (3MS) and Trail Making Test Part B (Trails B) in a cohort of 1,604 men enrolled in the Osteoporotic Fractures in Men Study and followed them for an average of 4.6 years for changes in cognitive function. RESULTS: In a model adjusted for age, season, and site, men with lower 25(OH)D levels seemed to have a higher odds of cognitive impairment, but the test for trend did not reach significance (impairment by 3MS: odds ratio [OR] 1.84, 95% confidence interval [CI] 0.81-4.19 for quartile [Q] 1; 1.41, 0.61-3.28 for Q2; and 1.18, 0.50-2.81 for Q3, compared with Q4 [referent group; p trend = 0.12]; and impairment by Trails B: OR 1.66, 95% CI 0.98-2.82 for Q1; 0.96, 0.54-1.69 for Q2; and 1.30, 0.76-2.22 for Q3, compared with Q4 [p trend = 0.12]). Adjustment for age and education further attenuated the relationships. There was a trend for an independent association between lower 25(OH)D levels and odds of cognitive decline by 3MS performance (multivariable OR 1.41, 95% CI 0.89-2.23 for Q1; 1.28, 0.84-1.95 for Q2; and 1.06, 0.70-1.62 for Q3, compared with Q4 [p = 0.10]), but no association with cognitive decline by Trails B. CONCLUSION: We found little evidence of independent associations between lower 25-hydroxyvitamin D level and baseline global and executive cognitive function or incident cognitive decline.

Original languageEnglish (US)
Pages (from-to)33-41
Number of pages9
JournalNeurology
Volume74
Issue number1
DOIs
StatePublished - Jan 2010
Externally publishedYes

Fingerprint

Cognition
Odds Ratio
Confidence Intervals
Trail Making Test
Osteoporotic Fractures
Executive Function
25-hydroxyvitamin D
Cognitive Dysfunction
Education

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Slinin, Y., Paudel, M. L., Taylor, B. C., Fink, H. A., Ishani, A., Canales, M. T., ... Ensrud, K. E. (2010). 25-Hydroxyvitamin D levels and cognitive performance and decline in elderly men. Neurology, 74(1), 33-41. https://doi.org/10.1212/WNL.0b013e3181c7197b

25-Hydroxyvitamin D levels and cognitive performance and decline in elderly men. / Slinin, Y.; Paudel, M. L.; Taylor, B. C.; Fink, H. A.; Ishani, A.; Canales, M. T.; Yaffe, K.; Barrett-Connor, E.; Orwoll, Eric; Shikany, J. M.; Leblanc, E. S.; Cauley, J. A.; Ensrud, K. E.

In: Neurology, Vol. 74, No. 1, 01.2010, p. 33-41.

Research output: Contribution to journalArticle

Slinin, Y, Paudel, ML, Taylor, BC, Fink, HA, Ishani, A, Canales, MT, Yaffe, K, Barrett-Connor, E, Orwoll, E, Shikany, JM, Leblanc, ES, Cauley, JA & Ensrud, KE 2010, '25-Hydroxyvitamin D levels and cognitive performance and decline in elderly men', Neurology, vol. 74, no. 1, pp. 33-41. https://doi.org/10.1212/WNL.0b013e3181c7197b
Slinin Y, Paudel ML, Taylor BC, Fink HA, Ishani A, Canales MT et al. 25-Hydroxyvitamin D levels and cognitive performance and decline in elderly men. Neurology. 2010 Jan;74(1):33-41. https://doi.org/10.1212/WNL.0b013e3181c7197b
Slinin, Y. ; Paudel, M. L. ; Taylor, B. C. ; Fink, H. A. ; Ishani, A. ; Canales, M. T. ; Yaffe, K. ; Barrett-Connor, E. ; Orwoll, Eric ; Shikany, J. M. ; Leblanc, E. S. ; Cauley, J. A. ; Ensrud, K. E. / 25-Hydroxyvitamin D levels and cognitive performance and decline in elderly men. In: Neurology. 2010 ; Vol. 74, No. 1. pp. 33-41.
@article{fc2b9861913b4122a3be1a517439b7f5,
title = "25-Hydroxyvitamin D levels and cognitive performance and decline in elderly men",
abstract = "OBJECTIVE: To test the hypothesis that lower 25-hydroxyvitamin D [25(OH)D] levels are associated with a greater likelihood of cognitive impairment and risk of cognitive decline. METHODS: We measured 25(OH)D and assessed cognitive function using the Modified Mini-Mental State Examination (3MS) and Trail Making Test Part B (Trails B) in a cohort of 1,604 men enrolled in the Osteoporotic Fractures in Men Study and followed them for an average of 4.6 years for changes in cognitive function. RESULTS: In a model adjusted for age, season, and site, men with lower 25(OH)D levels seemed to have a higher odds of cognitive impairment, but the test for trend did not reach significance (impairment by 3MS: odds ratio [OR] 1.84, 95{\%} confidence interval [CI] 0.81-4.19 for quartile [Q] 1; 1.41, 0.61-3.28 for Q2; and 1.18, 0.50-2.81 for Q3, compared with Q4 [referent group; p trend = 0.12]; and impairment by Trails B: OR 1.66, 95{\%} CI 0.98-2.82 for Q1; 0.96, 0.54-1.69 for Q2; and 1.30, 0.76-2.22 for Q3, compared with Q4 [p trend = 0.12]). Adjustment for age and education further attenuated the relationships. There was a trend for an independent association between lower 25(OH)D levels and odds of cognitive decline by 3MS performance (multivariable OR 1.41, 95{\%} CI 0.89-2.23 for Q1; 1.28, 0.84-1.95 for Q2; and 1.06, 0.70-1.62 for Q3, compared with Q4 [p = 0.10]), but no association with cognitive decline by Trails B. CONCLUSION: We found little evidence of independent associations between lower 25-hydroxyvitamin D level and baseline global and executive cognitive function or incident cognitive decline.",
author = "Y. Slinin and Paudel, {M. L.} and Taylor, {B. C.} and Fink, {H. A.} and A. Ishani and Canales, {M. T.} and K. Yaffe and E. Barrett-Connor and Eric Orwoll and Shikany, {J. M.} and Leblanc, {E. S.} and Cauley, {J. A.} and Ensrud, {K. E.}",
year = "2010",
month = "1",
doi = "10.1212/WNL.0b013e3181c7197b",
language = "English (US)",
volume = "74",
pages = "33--41",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - 25-Hydroxyvitamin D levels and cognitive performance and decline in elderly men

AU - Slinin, Y.

AU - Paudel, M. L.

AU - Taylor, B. C.

AU - Fink, H. A.

AU - Ishani, A.

AU - Canales, M. T.

AU - Yaffe, K.

AU - Barrett-Connor, E.

AU - Orwoll, Eric

AU - Shikany, J. M.

AU - Leblanc, E. S.

AU - Cauley, J. A.

AU - Ensrud, K. E.

PY - 2010/1

Y1 - 2010/1

N2 - OBJECTIVE: To test the hypothesis that lower 25-hydroxyvitamin D [25(OH)D] levels are associated with a greater likelihood of cognitive impairment and risk of cognitive decline. METHODS: We measured 25(OH)D and assessed cognitive function using the Modified Mini-Mental State Examination (3MS) and Trail Making Test Part B (Trails B) in a cohort of 1,604 men enrolled in the Osteoporotic Fractures in Men Study and followed them for an average of 4.6 years for changes in cognitive function. RESULTS: In a model adjusted for age, season, and site, men with lower 25(OH)D levels seemed to have a higher odds of cognitive impairment, but the test for trend did not reach significance (impairment by 3MS: odds ratio [OR] 1.84, 95% confidence interval [CI] 0.81-4.19 for quartile [Q] 1; 1.41, 0.61-3.28 for Q2; and 1.18, 0.50-2.81 for Q3, compared with Q4 [referent group; p trend = 0.12]; and impairment by Trails B: OR 1.66, 95% CI 0.98-2.82 for Q1; 0.96, 0.54-1.69 for Q2; and 1.30, 0.76-2.22 for Q3, compared with Q4 [p trend = 0.12]). Adjustment for age and education further attenuated the relationships. There was a trend for an independent association between lower 25(OH)D levels and odds of cognitive decline by 3MS performance (multivariable OR 1.41, 95% CI 0.89-2.23 for Q1; 1.28, 0.84-1.95 for Q2; and 1.06, 0.70-1.62 for Q3, compared with Q4 [p = 0.10]), but no association with cognitive decline by Trails B. CONCLUSION: We found little evidence of independent associations between lower 25-hydroxyvitamin D level and baseline global and executive cognitive function or incident cognitive decline.

AB - OBJECTIVE: To test the hypothesis that lower 25-hydroxyvitamin D [25(OH)D] levels are associated with a greater likelihood of cognitive impairment and risk of cognitive decline. METHODS: We measured 25(OH)D and assessed cognitive function using the Modified Mini-Mental State Examination (3MS) and Trail Making Test Part B (Trails B) in a cohort of 1,604 men enrolled in the Osteoporotic Fractures in Men Study and followed them for an average of 4.6 years for changes in cognitive function. RESULTS: In a model adjusted for age, season, and site, men with lower 25(OH)D levels seemed to have a higher odds of cognitive impairment, but the test for trend did not reach significance (impairment by 3MS: odds ratio [OR] 1.84, 95% confidence interval [CI] 0.81-4.19 for quartile [Q] 1; 1.41, 0.61-3.28 for Q2; and 1.18, 0.50-2.81 for Q3, compared with Q4 [referent group; p trend = 0.12]; and impairment by Trails B: OR 1.66, 95% CI 0.98-2.82 for Q1; 0.96, 0.54-1.69 for Q2; and 1.30, 0.76-2.22 for Q3, compared with Q4 [p trend = 0.12]). Adjustment for age and education further attenuated the relationships. There was a trend for an independent association between lower 25(OH)D levels and odds of cognitive decline by 3MS performance (multivariable OR 1.41, 95% CI 0.89-2.23 for Q1; 1.28, 0.84-1.95 for Q2; and 1.06, 0.70-1.62 for Q3, compared with Q4 [p = 0.10]), but no association with cognitive decline by Trails B. CONCLUSION: We found little evidence of independent associations between lower 25-hydroxyvitamin D level and baseline global and executive cognitive function or incident cognitive decline.

UR - http://www.scopus.com/inward/record.url?scp=74049134320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049134320&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e3181c7197b

DO - 10.1212/WNL.0b013e3181c7197b

M3 - Article

C2 - 19940271

AN - SCOPUS:74049134320

VL - 74

SP - 33

EP - 41

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 1

ER -